Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells

Abstract excerpt

Recent clinical trials have shown that evasion of CD8(+) T-cell responses against viral capsid is critical for successful liver-directed gene therapy with adeno-associated viral (AAV) vectors for hemophilia. Preclinical models to test whether use of alternate serotypes or capsid variants could avoid this deleterious response have been lacking. Here, the ability of CD8(+) T cells ("cap-CD8," specific for a capsid...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to RNA Interference and Gene Delivery
• Share to SARS-CoV-2 and COVID-19 Research
• Share to Virus-based gene therapy research